Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Thromboembolism 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Esophageal Neoplasms 1

Interventions

pembrolizumab 27Oxaliplatin 24Paclitaxel 22Fluorouracil 21Carboplatin 18Leucovorin 16Cisplatin 16Capecitabine 16Radiotherapy 15Nivolumab 12Drug Therapy 12Radiation 10Trastuzumab 9Surgical Procedures, Operative 8Immunotherapy 8Magnetic Resonance Spectroscopy 7Esophagectomy 7Blood Specimen Collection 7Taxes 6tislelizumab 5durvalumab 5Surveys and Questionnaires 5Specimen Handling 5Radiotherapy, Intensity-Modulated 5Irinotecan 5Immune Checkpoint Inhibitors 5Docetaxel 5Bevacizumab 5Ramucirumab 4Fluorodeoxyglucose F18 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × PEGPH20 × 1 year × Clear all
NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Hoffmann-La Roche

Phase 1/2 Completed
214 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡